What This Case Does and Does Not Show

What is supported: the A1c, the home glucose log, and the same-day central-lab glucose in this case are each analytically plausible on their own. The patient's CKD, anemia, and ESA therapy make altered red-cell survival a leading explanation for the discordance, but the sparse fasting-weighted glucose record does not prove that cause or exclude an assay problem. Fructosamine, glycated albumin, or a CGM/structured glucose review are reasonable next checks because they do not share that same red-cell-survival dependency and can test the hypothesis.

What is not supported: no source used here gives a single, universally applicable numeric conversion between A1c and fructosamine or glycated albumin. No firm dialysis-specific A1c numeric target was found in the guidance reviewed either; KDIGO flags A1c as unreliable in that population rather than naming a replacement number, and that gap is an open question, not a number to invent.

When short-term glucose data and A1c disagree, name the explanation you can support, name the check that will test it, and leave the treatment decision to the clinician working within local policy.